GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (NAS:SNY) » Definitions » Balance Sheet Cash And Cash Equivalents
中文

Sanofi (Sanofi) Balance Sheet Cash And Cash Equivalents


View and export this data going back to 2002. Start your Free Trial

Please go to this page to see Cash And Cash Equivalents for non-financial companies.


Sanofi (Sanofi) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (NAS:SNY) » Definitions » Balance Sheet Cash And Cash Equivalents
Address
46, avenue de la Grande Armée, Paris, FRA, 75017
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 15% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.